Quick Answer
Spyre Therapeutics, Inc. reported Stockholders Equity of $715.24 million for fiscal year 2025.
Spyre Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $715.24M | +38.1% |
| 2024 | $517.80M | +181.4% |
| 2023 | $184.02M | +265.8% |
| 2022 | $50.30M | -40.1% |
| 2021 | $83.94M | -40.0% |
| 2020 | $139.83M | +132.7% |
| 2019 | $60.08M | -10.9% |
| 2018 | $67.43M | +34.0% |
| 2017 | $50.34M | -20.1% |
| 2016 | $62.97M | +383.5% |
| 2015 | -$22.21M | -93.6% |
| 2014 | -$11.47M | -801.3% |
| 2013 | -$1.27M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $455.10M | +39.0% | -0.1% |
| June 30, 2025 | $455.77M | +21.7% | -5.6% |
| March 31, 2025 | $482.61M | +216.9% | -6.8% |
| December 31, 2024 | $517.80M | +181.4% | +58.2% |
| September 30, 2024 | $327.39M | +233.4% | -12.6% |
| June 30, 2024 | $374.38M | +280.5% | +145.9% |
| March 31, 2024 | $152.27M | +352.5% | -17.3% |
| December 31, 2023 | $184.02M | +265.8% | +175.0% |
- Spyre Therapeutics, Inc. showed an increase of +38.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2013–2025 period, Spyre Therapeutics, Inc.’s stockholders equity has grown by 56285.1% (from -$1.27 million to $715.24 million).
- The most recent figure is from Spyre Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: